Erratum to: Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis

Erratum to: Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A... Cardiovasc Intervent Radiol (2017) 40:1487 DOI 10.1007/s00270-017-1693-2 ERRATUM Erratum to: Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis 1 1 1 1 1 • • • • • Laila Lobo Danny Yakoub Omar Picado Caroline Ripat Fiorella Pendola 1 1 2 3 • • • • Rishika Sharma Rana ElTawil Deukwoo Kwon Shree Venkat 4 4,5 Loraine Portelance Raphael Yechieli Published online: 25 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 Erratum to: Cardiovasc Intervent Radiol (2016) Line: 11 39:1580–1588 Word: 2 DOI 10.1007/s00270-016-1426-y TACE should be changed to TARE Line: 13 Corrections to the last section (‘‘Survival’’) on page 1582: Word: 6 Line: 7 TARE should be changed to TACE Word: 3 The complete corrected section appears below. TARE should be changed to TACE Survival Word: 9 Survival information was extracted from the five studies. TACE should be changed to TARE This included 284 patients undergoing TACE and 269 Line: 10 patients undergoing TARE. Male to female ratio for TACE Word: 4 is 82:18 and for TARE is 77:23. Median age for TACE is TARE should be changed to TACE 63 with a range of 33–88, whereas TARE is 64 with range of 29–88. Overall survival at 1 year was 42% for TACE subjects compared to 46% for TARE. Statistically there The online version of the original article can be found under doi:10. was no difference noticed between 2 modalities 1007/s00270-016-1426-y. (RR = 0.93, 95% CI 0.81–1.08, p = 0.33). At 2 years more TACE patients were alive than those that received & Raphael Yechieli TARE (27 vs. 18%) the difference of which was statisti- ryechieli@med.miami.edu cally significant (RR = 1.36, 95% CI 1.05–1.76, Division of Surgical Oncology at Department of Surgery, p = 0.02). At 3 years more TACE patients survived (14 vs. Sylvester Comprehensive Cancer Center, University of 8%) yet no statistically significant difference was noted Miami - Miller School of Medicine, Miami, FL, USA (RR = 1.27, 95% CI 0.88–1.84, p = 0.20). At 4 years Department of Biostatistics and Bioinformatics, Sylvester subjects alive from both TACE and TARE were 4% with Comprehensive Cancer Center, University of Miami - Miller no statistically significant difference in survival School of Medicine, Miami, FL, USA 3 (RR = 1.64, 95% CI 0.80–3.34, p = 0.17). At 5 years only Department of Radiology, Sylvester Comprehensive Cancer 1% of subject population was alive from both TACE and Center, University of Miami - Miller School of Medicine, Miami, FL, USA TARE treatment modalities. There was minimal hetero- geneity among studies (p [ 0.05). Disease-specific mor- Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami - Miller tality (RR = 1.58, 95% CI 0.49–5.10, p = 0.44) did not School of Medicine, Miami, FL, USA show difference between studies but high heterogeneity Department of Radiation Oncology, Jackson Memorial was noted (p2 = 0.6462, p = 0.0015, I2 = 90%). Hospital/Sylvester Comprehensive Cancer Center, University of Miami - Miller School of Medicine, 1475 NW 12th Ave, Suite 1500, Miami, FL 33136, USA http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CardioVascular and Interventional Radiology Springer Journals

Erratum to: Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/erratum-to-unresectable-hepatocellular-carcinoma-radioembolization-20QFWJFa75
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Subject
Medicine & Public Health; Imaging / Radiology; Cardiology; Nuclear Medicine; Ultrasound
ISSN
0174-1551
eISSN
1432-086X
D.O.I.
10.1007/s00270-017-1693-2
Publisher site
See Article on Publisher Site

Abstract

Cardiovasc Intervent Radiol (2017) 40:1487 DOI 10.1007/s00270-017-1693-2 ERRATUM Erratum to: Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis 1 1 1 1 1 • • • • • Laila Lobo Danny Yakoub Omar Picado Caroline Ripat Fiorella Pendola 1 1 2 3 • • • • Rishika Sharma Rana ElTawil Deukwoo Kwon Shree Venkat 4 4,5 Loraine Portelance Raphael Yechieli Published online: 25 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 Erratum to: Cardiovasc Intervent Radiol (2016) Line: 11 39:1580–1588 Word: 2 DOI 10.1007/s00270-016-1426-y TACE should be changed to TARE Line: 13 Corrections to the last section (‘‘Survival’’) on page 1582: Word: 6 Line: 7 TARE should be changed to TACE Word: 3 The complete corrected section appears below. TARE should be changed to TACE Survival Word: 9 Survival information was extracted from the five studies. TACE should be changed to TARE This included 284 patients undergoing TACE and 269 Line: 10 patients undergoing TARE. Male to female ratio for TACE Word: 4 is 82:18 and for TARE is 77:23. Median age for TACE is TARE should be changed to TACE 63 with a range of 33–88, whereas TARE is 64 with range of 29–88. Overall survival at 1 year was 42% for TACE subjects compared to 46% for TARE. Statistically there The online version of the original article can be found under doi:10. was no difference noticed between 2 modalities 1007/s00270-016-1426-y. (RR = 0.93, 95% CI 0.81–1.08, p = 0.33). At 2 years more TACE patients were alive than those that received & Raphael Yechieli TARE (27 vs. 18%) the difference of which was statisti- ryechieli@med.miami.edu cally significant (RR = 1.36, 95% CI 1.05–1.76, Division of Surgical Oncology at Department of Surgery, p = 0.02). At 3 years more TACE patients survived (14 vs. Sylvester Comprehensive Cancer Center, University of 8%) yet no statistically significant difference was noted Miami - Miller School of Medicine, Miami, FL, USA (RR = 1.27, 95% CI 0.88–1.84, p = 0.20). At 4 years Department of Biostatistics and Bioinformatics, Sylvester subjects alive from both TACE and TARE were 4% with Comprehensive Cancer Center, University of Miami - Miller no statistically significant difference in survival School of Medicine, Miami, FL, USA 3 (RR = 1.64, 95% CI 0.80–3.34, p = 0.17). At 5 years only Department of Radiology, Sylvester Comprehensive Cancer 1% of subject population was alive from both TACE and Center, University of Miami - Miller School of Medicine, Miami, FL, USA TARE treatment modalities. There was minimal hetero- geneity among studies (p [ 0.05). Disease-specific mor- Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami - Miller tality (RR = 1.58, 95% CI 0.49–5.10, p = 0.44) did not School of Medicine, Miami, FL, USA show difference between studies but high heterogeneity Department of Radiation Oncology, Jackson Memorial was noted (p2 = 0.6462, p = 0.0015, I2 = 90%). Hospital/Sylvester Comprehensive Cancer Center, University of Miami - Miller School of Medicine, 1475 NW 12th Ave, Suite 1500, Miami, FL 33136, USA

Journal

CardioVascular and Interventional RadiologySpringer Journals

Published: May 25, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off